Portola Pharma (PTLA) Reports In-Line Q1 EPS, Revenues Beat

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.02), in-line with the analyst estimate of ($1.02). Revenue for the quarter came in at $22.17 million versus the consensus estimate of $19.18 million.

“Our first quarter results continue to reflect strong demand for Andexxa, as well as focused execution on our commercial launch. The full commercial U.S. launch of Andexxa is off to a great start, and with approval of Ondexxya in Europe, we now have another long-term growth catalyst and the ability to impact thousands of additional patient lives,” said Scott Garland, Portola’s president and chief executive officer. “Additionally, we continue to make progress with cerdulatinib and look forward to further defining its safety and efficacy profile, along with that of Andexxa, in a number of scientific presentations anticipated in Q2.”

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c